Q-omics provides the consensus-scored PPM1D profile across patient tissues and cancer cell-line models. PPM1D expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPM1D is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, PPM1D RNA expression shows 20,796 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where PPM1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1D survival associations across molecular data types. PPM1D RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1D RNA expression–survival associations across cancer types. High PPM1D expression shows unfavorable associations in MESO, but favorable associations in KIRC, HNSC, UCS, COAD and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPM1D RNA expression.
This table summarizes PPM1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PPM1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1D shows lower tumor expression in KICH, THCA, LUAD and LUSC and higher tumor expression in KIRP and KIRC. The KIRP box plot shows higher PPM1D RNA expression in tumor versus normal tissue (log2 FC = +0.827, t-test p < 0.001).
This table shows molecular features associated with PPM1D in patient tissues and cancer cell lines. In patient samples, PPM1D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPM1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
